glp-1 agonist weight gain effects receptor agonists for individualized treatment of type 2 diabetes mellitus Novo Nordisk to slash Size:120 digestive-support

glp-1 agonist weight gain effects receptor agonists for individualized treatment of type 2 diabetes mellitus Novo Nordisk to slash Size:120 digestive-support

Novo Nordisk to slash GLP-1 list prices by up to 50% in US to cut costs for insured patients

Data were extracted as follows: (1) species, number exposed to drug of interest, number of controls, timing and duration of exposure, dose (drug/kg/time-interval and equivalents to maximum recommended human dosage or clinical dosage), fetal effects of maternal GLP-1 agonist or SGLT2 inhibitor exposure, (2) species, number exposed to drug of interest, number of controls, timing and duration of exposure, dose (drug/kg/time-interval and equivalents to maximum recommended human dosage or clinical dosage), the transfer of GLP-1 agonist or SGLT2 inhibitor in maternal milk and the effect of exposure during lactation on the neonate

digestive-support

Size:120

For employers, these developments could lead to shifts in formulary decisions and cost-sharing strategies